NYSE:MNK

Mallinckrodt (MNK) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $0.04
▼
$0.09
50-Day Range: $0.14
▼
$0.75
52-Week Range: $0.75
▼
$6.42

Volume: 1,924 shs
Average Volume: 2.62 million shs
Market Capitalization: $1.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Mallinckrodt (NYSE:MNK) Stock

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

September 20, 2023 | msn.com

Firm Retention Summary: Mallinckrodt

September 20, 2023 | msn.com

Drug giant Mallinckrodt enters second Irish Examinership

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 19, 2023 | msn.com

Bankrupt Drugmaker Mallinckrodt Considers Sale of Opioid Business

September 1, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)

August 31, 2023 | finance.yahoo.com

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

August 30, 2023 | finance.yahoo.com

Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

August 28, 2023 | msn.com

Mallinckrodt files for bankruptcy for a second time

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

August 28, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)

August 28, 2023 | bizjournals.com

Mallinckrodt bankruptcy shows millions owed to NC firms, state

August 28, 2023 | msn.com

Mallinckrodt discloses grand jury subpoena, makes bankruptcy filing official

August 28, 2023 | msn.com

Hit By Opioid Lawsuits Mallinckrodt Files For Second Bankruptcy In Just Three Years

August 28, 2023 | bizjournals.com

Drug maker Mallinckrodt again files for bankruptcy, as planned

August 28, 2023 | benzinga.com

Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

August 28, 2023 | nasdaq.com

Mallinckrodt Initiates Voluntary Prepackaged Chapter 11 Proceedings In U.S. Bankruptcy Court

August 28, 2023 | msn.com

Drugmaker Mallinckrodt files for second bankruptcy in the US

August 28, 2023 | finance.yahoo.com

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

August 24, 2023 | msn.com

Mallinckrodt Lenders to Take Control in Bankruptcy That Cuts $1 Billion in Opioid Payments

August 23, 2023 | bizjournals.com

Drug maker Mallinckrodt to again file for bankruptcy protection

August 23, 2023 | msn.com

Mallinckrodt second bankruptcy would cut $1 billion from opioid settlement

August 23, 2023 | markets.businessinsider.com

Mallinckrodt Inks RSA To Initiate Voluntary Prepackaged Chapter 11 Proceedings

August 23, 2023 | markets.businessinsider.com

Mallinckrodt To Initiate Chapter 11 Bankruptcy Proceedings

August 23, 2023 | msn.com

U.S. drugmaker Mallinckrodt plans to file for bankruptcy protection

August 23, 2023 | proactiveinvestors.com

Mallinckrodt stock tumbles on plans to file for Chapter 11 bankruptcy for second time in three years

August 23, 2023 | msn.com

Mallinckrodt to file for prepackaged Chapter 11 bankruptcy and cut about $1.9 billion in debt

August 23, 2023 | msn.com

150-Year Old Opioid Drugmaker Mallinckrodt Files For Bankruptcy For Second Time

See More Headlines

Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

MNK Company Calendar

Last Earnings: 8/09/2023
Today: 10/02/2023
Next Earnings (Estimated): 12/18/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:MNK
CUSIP: N/A
CIK: 1567892
Web: www.mallinckrodt.com
Phone: (531) 696-0000
Fax: N/A
Employees: 2,700
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($116.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: -82.59%
Pretax Margin: N/A
Return on Equity: 20.32%
Return on Assets: 2.49%

Debt

Debt-to-Equity Ratio: 1.18
Current Ratio: 0.57
Quick Ratio: 0.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $47.48 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 13,170,000
Free Float: 13,131,000
Market Cap: $1.12 million
Optionable: Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mark C. Trudeau
President, Chief Executive Officer & Director

Bryan M. Reasons
Chief Financial Officer & Executive Vice President

Steven Joseph Romano
Chief Scientific Officer & Executive VP

Babatunde Adekunle Otulana
Chief Medical Officer & Senior Vice President

Michele Robertson
Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNK Stock - Frequently Asked Questions

When is Mallinckrodt's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 18th 2023.
View our MNK earnings forecast.
How were Mallinckrodt's earnings last quarter?: Mallinckrodt plc (NYSE:MNK) issued its earnings results on Wednesday, August, 9th. The company reported ($1.45) earnings per share for the quarter. The firm earned $475 million during the quarter. Mallinckrodt had a positive trailing twelve-month return on equity of 20.32% and a negative net margin of 82.59%.
What guidance has Mallinckrodt issued on next quarter's earnings?: Mallinckrodt issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.70 billion-$1.82 billion.
What other stocks do shareholders of Mallinckrodt own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD).

What is Mallinckrodt's stock symbol?: Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
What is Mallinckrodt's stock price today?: One share of MNK stock can currently be purchased for approximately $0.09.
How much money does Mallinckrodt make?: Mallinckrodt (NYSE:MNK) has a market capitalization of $1.12 million.
How many employees does Mallinckrodt have?: The company employs 2,700 workers across the globe.
How can I contact Mallinckrodt?: Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The official website for the company is www.mallinckrodt.com. The company can be reached via phone at (531) 696-0000 or via email at investor.relations@mnk.com.

This page (NYSE:MNK) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mallinckrodt (MNK) Stock Forecast, Price & News

About Mallinckrodt (NYSE:MNK) Stock

MNK Stock News Headlines

MNK Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MNK Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info